Aberrant ARMCX1 Expression Is an Independent Predictor of Poor Prognosis in Gastric Cancer

Table 1

Association between ARMCX1 expression and clinicopathologic characteristics in TCGA and our validation cohort.

TCGA cohort		Total	ARMCX1 expression
			Low expression	High expression
Age	<65	164	71	93	5.504	0.019
	≥65	207	115	92
Gender	Female	134	66	68	0.065	0.799
	Male	241	122	119
Tumor grade	G1	10	5	5	11.747	0.003
	G2	137	85	52
	G3	219	96	124
T stage	T1	19	18	1	18.969	<0.001
	T2	80	39	41
	T3	168	89	79
	T4	100	41	59
LN metastasis	Yes	246	119	127	2.639	0.104
	No	111	64	47
Distant metastasis	Yes	25	10	15	1.299	0.254
	No	330	171	159
TNM stage	Stage I	53	37	16	8.278	0.041
	Stage II	111	53	58
	Stage III	150	74	76
	Stage IV	38	18	20
Validation cohort
Age	<65	28	17	11	2.786	0.095
	≥65	24	9	15
Gender	Female	16	9	7	0.361	0.548
	Male	36	17	19
Tumor size	<5 cm	27	12	15	0.693	0.405
	≥5 cm	25	14	11
Tumor grade	G1 + G2	25	12	13	0.077	0.781
	G3	27	14	13
T stage	T1 + T2 + T3	25	8	15	3.945	0.047
	T4	27	19	6
LN metastasis	Yes	24	16	8	4.952	0.026
	No	28	10	18
TNM stage	Stage I/II	24	16	8	4.952	0.026
	Stage III	28	10	18

Italics indicated demonstrated by the chi-square test. Abbreviations: LN: lymph node metastasis.